Ascendis (Danish) makes long-acting hormone therapies.
Ascendis Pharma A/S (ASND) is expected to report earnings on Wednesday, November 11, 2026, after the close. Consensus EPS estimate is $0.91.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-13 | Jun 2026 qtr | $1.71 | $3.29 | — | $387.48M |
| 2026-05-07 | Mar 2026 qtr | $0.19 | $0.32 | — | $284.92M |
| 2025-11-12 | Sep 2025 qtr | $-0.41 | $-1.17 | — | $250.22M |
| 2025-08-07 | Jun 2025 qtr | $-1.42 | $-0.93 | — | $186.09M |
| 2025-05-01 | Mar 2025 qtr | $-1.56 | $-1.66 | -6.4% | $110.67M |
| 2025-02-12 | Dec 2024 qtr | $-1.20 | $-0.68 | — | $180.09M |
| 2024-11-14 | Sep 2024 qtr | $-1.83 | $-1.81 | +1.1% | $63.43M |
| 2024-09-03 | Jun 2024 qtr | $-1.54 | $-2.05 | — | $38.71M |
ASND has beaten consensus EPS in 1 of its last 2 scored quarters.
See ASND on the live calendar →